Purple Biotech Statistics

Total Valuation

Purple Biotech has a market cap or net worth of $5.59 million. The enterprise value is -$1.51 million.

Market Cap	5.59M
Enterprise Value	-1.51M

Important Dates

The next estimated earnings date is Tuesday, November 19, 2024, before market open.

Earnings Date	Nov 19, 2024
Ex-Dividend Date	n/a

Share Statistics

Purple Biotech has 275.32 million shares outstanding. The number of shares has increased by 30.82% in one year.

Shares Outstanding	275.32M
Shares Change (YoY)	+30.82%
Shares Change (QoQ)	+1.54%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	307.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.01.

Current Ratio	1.22
Quick Ratio	1.14
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -44.67% and return on invested capital (ROIC) is -33.77%.

Return on Equity (ROE)	-44.67%
Return on Assets (ROA)	-29.25%
Return on Capital (ROIC)	-33.77%
Revenue Per Employee	n/a
Profits Per Employee	-$801,550
Employee Count	20
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.49% in the last 52 weeks. The beta is 0.29, so Purple Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.29
52-Week Price Change	-88.49%
50-Day Moving Average	5.93
200-Day Moving Average	10.06
Relative Strength Index (RSI)	28.55
Average Volume (20 Days)	57,066

Short Selling Information

Short Interest	17,989
Short Previous Month	13,135
Short % of Shares Out	1.23%
Short % of Float	n/a
Short Ratio (days to cover)	0.38

Income Statement

Revenue	n/a
Gross Profit	-196,000
Operating Income	-19.67M
Pretax Income	18.76M
Net Income	-16.03M
EBITDA	-19.62M
EBIT	-19.67M
Earnings Per Share (EPS)	-$0.06

Full Income Statement

Balance Sheet

The company has $7.39 million in cash and $261,000 in debt, giving a net cash position of $7.13 million or $0.03 per share.

Cash & Cash Equivalents	7.39M
Total Debt	261,000
Net Cash	7.13M
Net Cash Per Share	$0.03
Equity (Book Value)	29.38M
Book Value Per Share	0.11
Working Capital	1.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$17.70 million and capital expenditures $1,000, giving a free cash flow of -$17.70 million.

Operating Cash Flow	-17.70M
Capital Expenditures	1,000
Free Cash Flow	-17.70M
FCF Per Share	-$0.06

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.82%
Shareholder Yield	-30.82%
Earnings Yield	-286.72%
FCF Yield	-316.48%

Analyst Forecast

The average price target for Purple Biotech is $126.50, which is 4,159.26% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$126.50
Price Target Difference	4,159.26%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 17, 2024. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Sep 17, 2024
Split Type	Reverse
Split Ratio	0.05:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a